Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Expected to Announce Earnings of -$0.76 Per Share

Wall Street brokerages forecast that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will report earnings of ($0.76) per share for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Lexicon Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.80) and the highest is ($0.71). Lexicon Pharmaceuticals posted earnings of ($0.16) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 375%. The business is scheduled to announce its next quarterly earnings results on Wednesday, March 11th.

On average, analysts expect that Lexicon Pharmaceuticals will report full-year earnings of $0.79 per share for the current year, with EPS estimates ranging from $0.71 to $0.87. For the next year, analysts expect that the business will post earnings of ($2.10) per share, with EPS estimates ranging from ($2.40) to ($1.94). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $2.11 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.31 by $0.80. Lexicon Pharmaceuticals had a return on equity of 2,372.40% and a net margin of 49.78%. The firm had revenue of $294.45 million during the quarter, compared to analysts’ expectations of $12.00 million. During the same quarter in the previous year, the business earned ($0.26) earnings per share. The company’s revenue was up 4124.5% on a year-over-year basis.

Several research firms have recently weighed in on LXRX. Wedbush restated a “buy” rating and issued a $17.00 price target on shares of Lexicon Pharmaceuticals in a research note on Sunday, December 22nd. BidaskClub cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, December 25th. Gabelli cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. They noted that the move was a valuation call. Zacks Investment Research cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, ValuEngine upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Eight equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Lexicon Pharmaceuticals has an average rating of “Hold” and an average target price of $6.50.

Shares of LXRX stock traded down $0.20 during mid-day trading on Friday, hitting $4.04. The company’s stock had a trading volume of 911,492 shares, compared to its average volume of 1,158,204. Lexicon Pharmaceuticals has a 52-week low of $1.13 and a 52-week high of $8.39. The business has a 50-day moving average price of $4.26 and a 200 day moving average price of $3.56. The company has a debt-to-equity ratio of 1.42, a quick ratio of 8.01 and a current ratio of 8.11. The stock has a market cap of $450.59 million, a price-to-earnings ratio of 3.12 and a beta of 1.02.

Institutional investors have recently bought and sold shares of the stock. Pictet Asset Management Ltd. increased its position in Lexicon Pharmaceuticals by 9.6% during the third quarter. Pictet Asset Management Ltd. now owns 729,876 shares of the biopharmaceutical company’s stock valued at $2,197,000 after acquiring an additional 64,100 shares during the last quarter. Millennium Management LLC increased its position in Lexicon Pharmaceuticals by 4.5% during the third quarter. Millennium Management LLC now owns 1,220,629 shares of the biopharmaceutical company’s stock valued at $3,674,000 after acquiring an additional 53,092 shares during the last quarter. Vanguard Group Inc. increased its position in Lexicon Pharmaceuticals by 8.1% during the second quarter. Vanguard Group Inc. now owns 4,240,111 shares of the biopharmaceutical company’s stock valued at $26,670,000 after acquiring an additional 319,382 shares during the last quarter. Morgan Stanley increased its position in Lexicon Pharmaceuticals by 158.0% during the second quarter. Morgan Stanley now owns 195,307 shares of the biopharmaceutical company’s stock valued at $1,229,000 after acquiring an additional 119,611 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new stake in Lexicon Pharmaceuticals during the third quarter valued at $202,000. Institutional investors own 96.24% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

See Also: Float

Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.